217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

BRCA models with high HRD scores. In addition, niraparib resistance or lack of in vivo efficacy was demonstrated in tumors with low HRD scores. Conclusion: HRD testing of ovarian cancer was predictive of BRCA deficiency. Response to niraparibwas seen in both BRCA and BRCA tumors. Our data are supportive of the use of HRD testing to select high grade ovarian cancer patients for the clinical evaluation of niraparib treatment.